Rising Prevalence of Hypertension Spurs Global Growth in New Therapies

Press Release (ePRNews.com) - WELLESLEY, Mass. - Feb 14, 2019 - Projected growth of the global antihypertensives market to 2023 is attributed to the growing prevalence of hypertension, an increase in government programs for prescription drugs, and investments by key players in the development of novel therapies.

The global market for antihypertensives was valued at $26.3 billion in 2018 and is expected to reach $27.8 billion in 2023 at a compound annual growth rate of 1.1% during the forecast period, according to the report “Antihypertensives: Global Markets to 2023.”

Major players in the industry include Johnson & JohnsonDaiichi Sankyo Co. LtdNovartis AG, and others.

Research Highlights:

  • The highest growth rate is projected for combination drugs due to their effectiveness, multiple patent exclusivities, and the growing preference of combination drugs over monotherapies in the treatment of hypertension.
  • By region, North America holds the largest market share, with anticipated growth driven by the adoption of new hypertension guidelines that are projected to increase the number of patients diagnosed with hypertension.
  • Asia-Pacific is forecast to experience the most growth, fueled by increasing awareness regarding hypertension management and public-private sector collaborations to provide affordable treatment in developing countries.

“Market growth has been spurred by the introduction of differentiated therapies with novel mechanisms of action, such as phosphodiesterase-5 inhibitors, stimulators of soluble guanylate cyclase, and endothelin receptor antagonists,” the report notes. “These provide powerful alternatives to currently prescribed antihypertensive drugs. The loss of patent exclusivity of blockbuster drugs and the increasing penetration of generics are market restraints.”

Novel Drug Molecules on the Rise

Following combination drugs, the second-largest market share is held by a segment that includes direct renin inhibitors, alpha blockers, phosphodiesterase-5 inhibitors, stimulators of soluble guanylate cyclase, endothelin receptor antagonists, vasodilators, and prostacyclin receptors. These other drug classes comprise a robust clinical pipeline that will boost growth.

Editors/reporters requesting analyst interviews should contact Eric Surber at press@bccresearch.com.

Source : BCC Research
Business Info :
BCC Research

You may also like this  


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.